Pregabalin Sandoz

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Sandoz GmbH

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Neuralgia; Epilepsy

Therapeutic indications:

Nevropatske painPregabalin Sandoz je primerna za zdravljenje periferne in centralne nevropatske bolečine pri odraslih. EpilepsyPregabalin Sandoz, je označeno kot adjunctive terapija pri odraslih z delni epileptični napadi z ali brez sekundarne posplošitev. Splošne Anksioznosti DisorderPregabalin Sandoz je primerna za zdravljenje Splošne Anksiozne Motnje (GAD) pri odraslih.

Product summary:

Revision: 17

Authorization status:

Pooblaščeni

Authorization date:

2015-06-19

Patient Information leaflet

                                26
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl
Avstrija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/15/1011/001-010
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pregabalin Sandoz 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC {številka}
SN {številka}
NN {številka}
27
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOTI
1.
IME ZDRAVILA
Pregabalin Sandoz 25 mg trde kapsule
pregabalin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sandoz
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
28
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI
ŠKATLA ZA VSEBNIK IN NALEPKA ZA VSEBNIK
1.
IME ZDRAVILA
Pregabalin Sandoz 25 mg trde kapsule
pregabalin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena trda kapsula vsebuje 25 mg pregabalina.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
200 trdih kapsul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
Uporabite v 6 mesecih od prvega odprtja.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
29
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl
A
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Pregabalin Sandoz 25 mg trde kapsule
Pregabalin Sandoz 50 mg trde kapsule
Pregabalin Sandoz 75 mg trde kapsule
Pregabalin Sandoz 100 mg trde kapsule
Pregabalin Sandoz 150 mg trde kapsule
Pregabalin Sandoz 200 mg trde kapsule
Pregabalin Sandoz 225 mg trde kapsule
Pregabalin Sandoz 300 mg trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Pregabalin Sandoz 25 mg trde kapsule
Ena trda kapsula vsebuje 25 mg pregabalina.
Pregabalin Sandoz 50 mg trde kapsule
Ena trda kapsula vsebuje 50 mg pregabalina.
Pregabalin Sandoz 75 mg trde kapsule
Ena trda kapsula vsebuje 75 mg pregabalina.
Pregabalin Sandoz 100 mg trde kapsule
Ena trda kapsula vsebuje 100 mg pregabalina.
Pregabalin Sandoz 150 mg trde kapsule
Ena trda kapsula vsebuje 150 mg pregabalina.
Pregabalin Sandoz 200 mg trde kapsule
Ena trda kapsula vsebuje 200 mg pregabalina.
Pregabalin Sandoz 225 mg trde kapsule
Ena trda kapsula vsebuje 225 mg pregabalina.
Pregabalin Sandoz 300 mg trde kapsule
Ena trda kapsula vsebuje 300 mg pregabalina.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trda kapsula
Pregabalin Sandoz 25 mg trde kapsule
Neprozorna pokrovček in telo blede rumenkasto-rjave barve, velikost
kapsule 4 (14,3 mm x 5,3 mm),
napolnjena s praškom bele do belkaste barve.
Pregabalin Sandoz 50 mg trde kapsule
Neprozorna pokrovček in telo svetlo rumene barve, velikost kapsule 3
(15,9 mm x 5,8 mm),
napolnjena s praškom bele do belkaste barve.
Pregabalin Sandoz 75 mg trde kapsule
Neprozoren pokrovček rdeče barve in neprozorno telo bele barve,
velikost kapsule 4 (14,3 mm x
5,3 mm), napolnjena s praškom bele do belkaste barve.
3
Pregabalin Sandoz 100 mg trde kapsule
Neprozorna pokrovček in telo blede rumenkasto-rjave barve, velikost
kapsule 4 (14,3 mm x 5,3 mm),
napolnjena s praškom bele do belkaste barve.
Pregabalin Sandoz 150 mg trde kapsule
Neprozorna pokrovček in telo rdeče barve, velikost kapsule 3 (15,9
mm x 5,8 mm), napolnjena s
praškom bele do belkaste barv
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-11-2023
Public Assessment Report Public Assessment Report Bulgarian 16-07-2015
Patient Information leaflet Patient Information leaflet Spanish 22-11-2023
Public Assessment Report Public Assessment Report Spanish 16-07-2015
Patient Information leaflet Patient Information leaflet Czech 22-11-2023
Public Assessment Report Public Assessment Report Czech 16-07-2015
Patient Information leaflet Patient Information leaflet Danish 22-11-2023
Public Assessment Report Public Assessment Report Danish 16-07-2015
Patient Information leaflet Patient Information leaflet German 22-11-2023
Public Assessment Report Public Assessment Report German 16-07-2015
Patient Information leaflet Patient Information leaflet Estonian 22-11-2023
Public Assessment Report Public Assessment Report Estonian 16-07-2015
Patient Information leaflet Patient Information leaflet Greek 22-11-2023
Public Assessment Report Public Assessment Report Greek 16-07-2015
Patient Information leaflet Patient Information leaflet English 22-11-2023
Public Assessment Report Public Assessment Report English 16-07-2015
Patient Information leaflet Patient Information leaflet French 22-11-2023
Public Assessment Report Public Assessment Report French 16-07-2015
Patient Information leaflet Patient Information leaflet Italian 22-11-2023
Public Assessment Report Public Assessment Report Italian 16-07-2015
Patient Information leaflet Patient Information leaflet Latvian 22-11-2023
Public Assessment Report Public Assessment Report Latvian 16-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 22-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-11-2023
Public Assessment Report Public Assessment Report Lithuanian 16-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 22-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 22-11-2023
Public Assessment Report Public Assessment Report Hungarian 16-07-2015
Patient Information leaflet Patient Information leaflet Maltese 22-11-2023
Public Assessment Report Public Assessment Report Maltese 16-07-2015
Patient Information leaflet Patient Information leaflet Dutch 22-11-2023
Public Assessment Report Public Assessment Report Dutch 16-07-2015
Patient Information leaflet Patient Information leaflet Polish 22-11-2023
Public Assessment Report Public Assessment Report Polish 16-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 22-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 22-11-2023
Public Assessment Report Public Assessment Report Portuguese 16-07-2015
Patient Information leaflet Patient Information leaflet Romanian 22-11-2023
Public Assessment Report Public Assessment Report Romanian 16-07-2015
Patient Information leaflet Patient Information leaflet Slovak 22-11-2023
Public Assessment Report Public Assessment Report Slovak 16-07-2015
Patient Information leaflet Patient Information leaflet Finnish 22-11-2023
Public Assessment Report Public Assessment Report Finnish 16-07-2015
Patient Information leaflet Patient Information leaflet Swedish 22-11-2023
Public Assessment Report Public Assessment Report Swedish 16-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 22-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 22-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 22-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 22-11-2023
Patient Information leaflet Patient Information leaflet Croatian 22-11-2023
Public Assessment Report Public Assessment Report Croatian 16-07-2015

Search alerts related to this product